81
Participants
Start Date
April 17, 2018
Primary Completion Date
July 16, 2019
Study Completion Date
July 16, 2019
Valbenazine
vesicular monoamine transporter 2 (VMAT2) inhibitor
Placebo oral capsule
non-active dosage form
Neurocrine Clinical Site, New York
Neurocrine Clinical Site, South Setauket
Neurocrine Clinical Site, Washington D.C.
Neurocrine Clinical Site, Charlottesville
Neurocrine Clinical Site, Charlotte
Neurocrine Clinical Site, Fayetteville
Neurocrine Clinical Site, Atlanta
Neurocrine Clinical Site, Savannah
Neurocrine Clinical Site, Tallahassee
Neurocrine Clinical Site, Gulf Breeze
Neurocrine Clinical Site, Orlando
Neurocrine Clinical Site, Hialeah
Neurocrine Clinical Site, Miami
Neurocrine Clinical Site, Miami
Neurocrine Clinical Site, Palmetto Bay
Neurocrine Clinical Site, North Miami
Neurocrine Clinical Site, St. Petersburg
Neurocrine Clinical Site, Spring Hill
Neurocrine Clinical Site, Mason
Neurocrine Clinical Site, South Bend
Neurocrine Clinical Site, Ann Arbor
Neurocrine Clinical Site, Bloomfield Hills
Neurocrine Clinical Site, West Bloomfield
Neurocrine Clinical Site, Chicago
Neurocrine Clinical Site, Lincoln
Neurocrine Clinical Site, Little Rock
Neurocrine Clinical Site, Rogers
Neurocrine Clinical Site, Oklahoma City
Neurocrine Clinical Site, Irving
Neurocrine Clinical Site, DeSoto
Neurocrine Clinical Site, Dallas
Neurocrine Clinical Site, Houston
Neurocrine Clinical Site, Houston
Neurocrine Clinical Site, San Antonio
Neurocrine Clinical Site, Pueblo
Neuricrine Clinical Site, Sun City
Neurocrine Clinical Site, San Diego
Neurocrine Clinical Site, Santa Ana
Neurocrine Clinical Site, Anaheim
Neurocrine Clinical Site, Fullerton
Neurocrine Clinical Site, Bothell
Neurocrine Clinical Site, Everett
Neurocrine Clinical Site, Spokane
Neurocrine Clinical Site, Stamford
Neurocrine Clinical Site, Boston
Neurocrine Clinical Site, Nashua
Neurocrine Clinical Site, Cherry Hill
Neurocrine Clinical Site, Mount Arlington
Neurocrine Clinical Site, San Juan
Lead Sponsor
Neurocrine Biosciences
INDUSTRY